Drug intelligence / Profile preview

EVOLENCE

Development stage: Unknown
Lead developer: Johnson & Johnson
Modality: Device-based Delivery → Drug Delivery Systems, Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intradermal (injection)

Overview

DP101 is referenced in the context of a clinical study titled "DP101-US-04," which was an open-label, multi-center, prospective, post-market study to assess the safety and effectiveness of EVOLENCE in facial augmentation for subjects with Fitzpatrick Skin Color Types IV, V, and VI. Based on this information, "DP101" appears to be a code name for EVOLENCE used during clinical development. EVOLENCE is an injectable dermal filler composed of porcine collagen cross-linked with D-ribose sugar. It is used for soft tissue augmentation to correct moderate-to-deep facial wrinkles and folds such as nasolabial folds.

Brand names: EVOLENCE

Beyond the preview

Go deeper on EVOLENCE.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EVOLENCE.

Explore the full profile